Judi R. Lum
Geen lopende functies
Profiel
Ms. Lum is Chief Financial Officer and VP of Finance.
She previously served as Chief Financial Officer of Inhale Therapeutic Systems (currently Nektar Therapeutics) where she was responsible for the accounting (including planning, tax, treasury and SEC reporting), human resources and IT functions.
At Inhale she participated in raising $75 million in public and private equity and established $15 million in debt financing.
Prior to Inhale she served as Chief Financial Officer at Soane Technologies, Director of Corporate Development at GenPharm International, Director of Finance at Raychem Corporation, and in finance and operations management capacities at Advanced Cardiovascular Systems.
Ms. Lum received both her Bachelor's Degree in Economics and her Master's Degree in Business Administration from Stanford University.
Eerdere bekende functies van Judi R. Lum
| Bedrijven | Functie | Einde |
|---|---|---|
StemCells, Inc.
 StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Financieel Directeur/CFO | 06-09-2005 |
Opleiding van Judi R. Lum
| Stanford University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Health Technology |
